Cogent Biosciences

Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.

Funding reportedLast round: Post ipo equity

BiotechnologyWaltham, United States

What company datasets say Cogent Biosciences raised

Funding, as reported

Reported in all$918Min dollars

Rounds10

Last roundPost ipo equity

Last round dateFeb 2024

Investors listed30

From Cogent Biosciences's own website: 8 on the team.

Andrew RobbinsChief Executive Officer
Courtney WatsonSenior Vice President, Head of Clinical Development Operations
Brad BarnettChief Technology Officer
Cole PinnowChief Commercial Officer
Erin SchellhammerChief People Officer
John GreenChief Financial Officer
Arlene M. MorrisTeam
Flatiron HealthTeam

Investors who name them

Each firm lists Cogent Biosciences on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Cogent Biosciences in front of investors. Or tell us what we have wrong.